Stock 4747 JOHNSON CHEMICAL PHARMACEUTICAL WORKS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Johnson Chemical Pharmaceutical Works Co., Ltd.

Equities

4747

TW0004747001

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 18:00:00 2024-06-25 EDT 		5-day change 1st Jan Change
72.2 TWD +0.28% Intraday chart for Johnson Chemical Pharmaceutical Works Co., Ltd. -0.41% -13.74%
05-17 Johnson Chemical Pharmaceutical Works Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-29 Johnson Chemical Pharmaceutical Works Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,166 1,171 1,117 1,052 1,537 3,655
Enterprise Value (EV) 1 856.4 861.2 951 929.9 1,428 2,728
P/E ratio 20.4 x 18.2 x 17.6 x 21.5 x 23.7 x 38.4 x
Yield 4.25% 4.62% 5.16% 4.14% 3.91% 1.79%
Capitalization / Revenue 2.83 x 2.75 x 2.63 x 2.56 x 3.11 x 6.02 x
EV / Revenue 2.08 x 2.02 x 2.24 x 2.26 x 2.89 x 4.5 x
EV / EBITDA 10.8 x 9.46 x 10.7 x 12 x 14.3 x 22.7 x
EV / FCF 17.2 x 19.2 x -8.95 x 93.8 x 90 x 33.8 x
FCF Yield 5.8% 5.22% -11.2% 1.07% 1.11% 2.95%
Price to Book 1.39 x 1.38 x 1.3 x 1.24 x 1.76 x 2.19 x
Nbr of stocks (in thousands) 30,019 30,019 30,019 30,019 30,019 43,668
Reference price 2 38.85 39.00 37.20 35.05 51.20 83.70
Announcement Date 19-03-28 20-03-30 21-03-25 22-03-31 23-03-30 24-03-29
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 411.9 425.3 424 411.5 494.7 606.7
EBITDA 1 79.21 91 89.24 77.57 100.1 119.9
EBIT 1 68.73 78.83 76.01 62.28 81.79 98.83
Operating Margin 16.69% 18.53% 17.93% 15.14% 16.54% 16.29%
Earnings before Tax (EBT) 1 70.9 81.44 76.55 61.94 81.53 100.9
Net income 1 57.28 64.47 63.56 49.1 64.85 79.7
Net margin 13.91% 15.16% 14.99% 11.93% 13.11% 13.14%
EPS 2 1.900 2.140 2.110 1.630 2.160 2.179
Free Cash Flow 1 49.67 44.96 -106.2 9.918 15.88 80.62
FCF margin 12.06% 10.57% -25.06% 2.41% 3.21% 13.29%
FCF Conversion (EBITDA) 62.71% 49.41% - 12.79% 15.87% 67.22%
FCF Conversion (Net income) 86.71% 69.74% - 20.2% 24.48% 101.15%
Dividend per Share 2 1.650 1.800 1.920 1.450 2.000 1.500
Announcement Date 19-03-28 20-03-30 21-03-25 22-03-31 23-03-30 24-03-29
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 310 310 166 122 108 927
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 49.7 45 -106 9.92 15.9 80.6
ROE (net income / shareholders' equity) 6.85% 7.65% 7.45% 5.75% 7.54% 6.27%
ROA (Net income/ Total Assets) 4.6% 5.22% 4.63% 3.66% 4.95% 4.07%
Assets 1 1,245 1,236 1,372 1,341 1,311 1,956
Book Value Per Share 2 27.90 28.20 28.60 28.30 29.00 38.30
Cash Flow per Share 2 10.30 10.30 9.850 6.740 5.610 24.90
Capex 1 7.33 15.1 162 37.3 59.7 33.1
Capex / Sales 1.78% 3.55% 38.25% 9.06% 12.07% 5.46%
Announcement Date 19-03-28 20-03-30 21-03-25 22-03-31 23-03-30 24-03-29
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
JOHNSON CHEMICAL PHARMACEUTICAL WORKS CO., LTD. Stock Johnson Chemical Pharmaceutical Works Co., Ltd.
-13.74% 99.49M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.61% 811B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.62% 640B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.62% 333B
ABBVIE INC. Stock AbbVie Inc.
+10.44% 302B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.89% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+2.54% 225B
NOVARTIS AG Stock Novartis AG
+12.97% 218B
AMGEN INC. Stock Amgen Inc.
+8.61% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4747 Stock
  4. Financials Johnson Chemical Pharmaceutical Works Co., Ltd.